These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444 [TBL] [Abstract][Full Text] [Related]
7. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Silverman LR; Mufti GJ Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236 [TBL] [Abstract][Full Text] [Related]
8. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Lübbert M Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943 [No Abstract] [Full Text] [Related]
9. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Tabarroki A; Saunthararajah Y; Visconte V; Cinalli T; Colaluca K; Rogers HJ; Sekeres MA; Duong HK; Stein BL; Tiu RV Leuk Lymphoma; 2015 Feb; 56(2):497-9. PubMed ID: 24766471 [No Abstract] [Full Text] [Related]
10. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes. Carella AM Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976 [No Abstract] [Full Text] [Related]
11. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878 [TBL] [Abstract][Full Text] [Related]
13. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. Sekeres MA; Steensma DP J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302 [No Abstract] [Full Text] [Related]
14. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Kuykendall JR Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884 [TBL] [Abstract][Full Text] [Related]
16. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469 [TBL] [Abstract][Full Text] [Related]
17. Drug therapy for myelodysplastic syndrome: building evidence for action. Tefferi A; Letendre L Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501 [No Abstract] [Full Text] [Related]
18. DNA methylation: its role in cancer development and therapy. Kurkjian C; Kummar S; Murgo AJ Curr Probl Cancer; 2008; 32(5):187-235. PubMed ID: 18926282 [No Abstract] [Full Text] [Related]
19. Clinical effectiveness of decitabine in severe sickle cell disease. Saunthararajah Y; Molokie R; Saraf S; Sidhwani S; Gowhari M; Vara S; Lavelle D; DeSimone J Br J Haematol; 2008 Apr; 141(1):126-9. PubMed ID: 18324975 [No Abstract] [Full Text] [Related]